Advertisement

A comparison of the pharmacokinetics of meropenem after intravenous administration by injection over 2, 3 and 5 minutes

  • H. K. Jones
  • H. C. Kelly
  • M. Hutchison
  • R. A. Yates
  • F. Ross
  • C. Lomax
  • S. Freestone
  • D. Webb
Article

Summary

The pharmacokinetics of meropenem were determined in 9 healthy volunteers after the administration of 1 g doses by injection over 2, 3 or 5 min. Peak plasma concentrations were not significantly different across the three rates of administration and, due to the finite time required for complete mixing of the blood in the central compartment, did not always occur at the end of the injection. Overall exposure to meropenem was unchanged by the more rapid rates of administration. Plasma clearance terminal half-life and volume of distribution were virtually unchanged. Within 10 min after the start of the injection, the plasma concentrations from all three injections were very similar indicating that dosing over 2, 3 or 5 min would result in similar antimicrobial cover and, therefore, comparable efficacy. Comparison of the data derived from the three injections indicated that rapid administration of meropenem did not appreciably alter its disposition pharmacokinetics. Tolerability of meropenem was unchanged with the more rapid administration rate.

Keywords

Meropenem pharmacokinetics carbapenem injection 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fukasawa M., Sumita Y., Harabe E.T., Tanio T., Nouda H., Kohzuki T. (1992): Stability of meropenem and the effect of 1β-methyl substitution on its stability in the presence of renal dehydropeptidase-I. Antimicrob. Agents Chemother., 36, 1577–1579.Google Scholar
  2. 2.
    Wiseman L.R., Wagstaff A.J., Brogden R.N., Bryson H.M. (1995): Meropenem. A Review of its antibacterial activity, Pharmacokinet Prop Clin Efficacy Drugs, 50, 73–101.Google Scholar
  3. 3.
    Edwards J.R. (1995): A microbiological overview. J. Antimicrob. Chemother., 6, Suppl A, 1–17.Google Scholar
  4. 4.
    Bax R.P., Bastain W., Featherstone A. Wilkinson D.M., Hutchison M., Haworth S.J. (1989): The pharmacokinetics of meropenem in volunteers. J. Antimicrob. Chemother., 24, Suppl. A, 311–320.PubMedGoogle Scholar
  5. 5.
    Burman L.A., Nilsson-Ehle I., Hutchison M., Haworth S.J., Norrby S.R. (1991): Pharmacokinetics of meropenem and its metabolite ICI 213, 689 in healthy subjects with known renal metabolism of imipenem. J. Antimicrob. Chemother., 27, 219–224.CrossRefPubMedGoogle Scholar
  6. 6.
    Christensson B.A., Nilsson-Ehle I., Hutchison M., Haworth S.J., Öqvist B., Norrby S.R. (1992): Pharmacokinetics of meropenem in subjects with various degrees of renal impairment. Antimicrob. Agents Chemother., 36, 1532–1537.PubMedGoogle Scholar
  7. 7.
    Leroy A., Fillastre J.P., Borsa-Lebas F., Étienne I. Humbert G. (1992): Pharmacokinetics of meropenem (ICI 194, 660) and its metabolite (ICI 213, 689) in healthy subjects and patients with renal impairment. Antimicrob. Agents Chemother., 36, 2794–2798.PubMedGoogle Scholar
  8. 8.
    Kelly H.C., Hutchison M., Haworth S.J. (1995): A comparison of the pharmacokinetics of meropenem after administration by intravenous injection over 5 min and intravenous infusion over 30 min. J. Antimicrob. Chemother., 36 Suppl. A., 35–41.PubMedGoogle Scholar
  9. 9.
    Harrison M.P., Moss S.R., Featherstone A., Fowkes A.G., Sanders A.M., Case D.E. (1989): The disposition and metabolism of meropenem in laboratory animals and man. J. Antimicrob. Chemother., 24, Suppl. A., 265–277.PubMedGoogle Scholar
  10. 10.
    Norrby S.R., Newell P.A., Faulkner K.K., Lesky W. (1995): Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem. J. Antimicrob. Chemother., 36, Suppl. A., 207–223.PubMedGoogle Scholar
  11. 11.
    Huizinga W.K.J., Warren B.L., Baker L.W. et al. (1995): Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections. J. Antimicrob. Chemother., 36 Suppl. A, 179–189.PubMedGoogle Scholar
  12. 12.
    Schuler D. and the Meropenem Paediatric Study Group (1995): Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. J. Antimicrob. Chemother., 36 Suppl. A, 99–108.PubMedGoogle Scholar
  13. 13.
    Klugman K.P., Friedland I.R., Bradley J.S. (1995): Bactericidal activity against cephalosporin-resistantStreptococcus pneumoniae in cerebrospinal fluid of children with acute bacterial meningitis. Antimicrob. Agents Chemother., 39, 1988–1992.PubMedGoogle Scholar
  14. 14.
    Bryne S., Maddison J., Connor P. et al. (1995): Clinical evaluation of meropenem versus ceftazidime for the treatment ofPseudomonas spp. infections, in cystic fibrosis patients. J. Antimicrob. Chemother., 36, Suppl. A, 135–143.Google Scholar
  15. 15.
    Allen G.D. (1990): MODFIT. A pharmacokinetics computer program. Biopharm. Drug Dispos., 11, 477–498.CrossRefPubMedGoogle Scholar
  16. 16.
    Norrby S.R., Vandercam B., Louie T. et al. (1987): Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomised multi-clinic study. Scand. J. Infect. Dis. Suppl., 52, 65–78.PubMedGoogle Scholar
  17. 17.
    Wang C., Calandra G.B., Aziz M.A., Brown K.R. (1985): Efficacy and safety of imipenem/cilastatin: a review of worldwide clinical experience. Rev. Infect. Dis., 7 Suppl. 3, S528-S536.PubMedGoogle Scholar
  18. 18.
    Gibson J.G., Evans W.A. (1937): Clinical studies of the blood volume Clinical application of a method employing the azo dye ‘Evans blue’ and the spectrophotometer. J. Clin. Invest., 16, 301–316.CrossRefPubMedGoogle Scholar
  19. 19.
    Chiou W.L. (1979): Potential pitfalls in the conventional pharmacokinetic studies: effects of the initial mixing of drug in blood and the pulmonary first-pass elimination. J. Pharmacokinet. Biopharm., 7, 572–536.CrossRefGoogle Scholar
  20. 20.
    Hinderling P.H., Garrett E.R. (1976): Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans. J. Pharmacokinet. Biopharm., 4, 199–230.CrossRefPubMedGoogle Scholar
  21. 21.
    Major E., Aun C., Yate P.M. et al. (1983): Influence of sample site on blood concentrations of ICI 35868. Br. J. Anaesth., 55, 371–375.CrossRefPubMedGoogle Scholar
  22. 22.
    Adam H.K., Briggs L.P., Bahar M., Douglas E.J., Dundee J.W. (1983): Pharmacokinetic evaluation of ICI 35868 in man. Br. J. Anaesth., 55, 97–103.CrossRefPubMedGoogle Scholar
  23. 23.
    Kaplin S.A., Jack M.L., Alexander K., Weinfield R.E. (1973): Pharmacokinetic profile of diazepam in man following single intravenous and oral and chronic oral administrations. J. Pharm. Sci., 62, 1789–1796.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1997

Authors and Affiliations

  • H. K. Jones
    • 2
  • H. C. Kelly
    • 2
  • M. Hutchison
    • 2
  • R. A. Yates
    • 2
  • F. Ross
    • 1
  • C. Lomax
    • 1
  • S. Freestone
    • 1
  • D. Webb
    • 1
  1. 1.Clinical Research CentreUniversity Department of Medicine, Western General HospitalEdinburghUK
  2. 2.Zeneca PharmaceuticalsMacclesfieldUK

Personalised recommendations